Antibody ID	ANI0RMKEH
Antibody Name	Anti-CD70 mAb IF6
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG
Antigen Name	CD70 antigen (CD70)					Antigen Info

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	19.75% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	525.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1096.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1585.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	66.35% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.15% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	84.59% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	85.01% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	1 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.25% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.90±2.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.10±2.70 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.10±3.60 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	86.68% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.40% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	168.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.33% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	95.90% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.39% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	44.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	275.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	339.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.88% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	1 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	16.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	19.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.91% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	1 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	95.00% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	98.65% (Day 30)	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	123.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	25.00 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	22.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	39.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	56.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1000.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10.00 uM	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10.00 uM	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10.00 uM	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Ref 1	Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate.